Hybridoma Cell Line H1.2F3 Producing Monoclonal Anti-mouse CD69 (Early activation marker) Antibody


A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
 
  • Speed up product development with NIH developed material that has already been tested and validated.


Inventors:

Ethan Shevach (NIAID)  ➽ more inventions...


Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1948-254)

Publications:
Yokoyama WM, et al. PMID 2838547

Licensing Contact:
Yogikala Prabhu,
Email: prabhuyo@niaid.nih.gov
Phone: 301-761-7789

OTT Reference No: B-004-1991/3
Updated: Dec 4, 2017